Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.59B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.04B |
| 3 |
Microsoft
MSFT
|
+$794M |
| 4 |
Home Depot
HD
|
+$512M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$357M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$491M |
| 2 |
Linde
LIN
|
+$373M |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$298M |
| 4 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$290M |
| 5 |
Salesforce
CRM
|
+$249M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.47% |
| 2 | Technology | 8.38% |
| 3 | Healthcare | 7.46% |
| 4 | Consumer Discretionary | 5.14% |
| 5 | Industrials | 5.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3451
Insmed
INSM
$25.9B
| $1.92M | ﹤0.01% |
90,862
-157,129
| -63% | -$2.98M |
|
3452
PUT
West Pharmaceutical
WST
$23.7B
| $1.91M | ﹤0.01% |
5,000
+2,000
| +67% | +$714K |
|
3453
PUT
Shake Shack
SHAK
$2.82B
| $1.91M | ﹤0.01% |
+24,600
| New | +$1.58M |
|
3454
Camping World
CWH
$417M
| $1.91M | ﹤0.01% |
63,461
-845,304
| -93% | -$21.3M |
|
3455
Philips
PHG
$26.1B
| $1.91M | ﹤0.01% |
+98,415
| New | +$1.72M |
|
3456
Nabors Industries
NBR
$1.39B
| $1.91M | ﹤0.01% |
20,517
-92,940
| -82% | -$9.45M |
|
3457
AtaiBeckley Inc
ATAI
$2.7B
| $1.91M | ﹤0.01% |
1,108,145
+374,334
| +51% | +$689K |
|
3458
Essent Group
ESNT
$6.19B
| $1.9M | ﹤0.01% |
+40,692
| New | +$1.77M |
|
|
AFMD
3459
DELISTED
Affimed
AFMD
| $1.9M | ﹤0.01% |
317,746
+143,530
| +82% | +$1.15M |
|
|
GRSD
3460
Grandstand Ltd
GRSD
$66.2M
| $1.9M | ﹤0.01% |
185,573
+150,377
| +427% | +$1.51M |
|
3461
Fulcrum Therapeutics
FULC
$294M
| $1.9M | ﹤0.01% |
574,857
-45,702
| -7% | -$134K |
|
3462
Adicet Bio
ACET
$84.8M
| $1.89M | ﹤0.01% |
48,730
+38,050
| +356% | +$3.36M |
|
3463
IAMGOLD
IAG
$11.8B
| $1.89M | ﹤0.01% |
718,608
-4,215,860
| -85% | -$12.2M |
|
3464
Abercrombie & Fitch
ANF
$6.59B
| $1.89M | ﹤0.01% |
50,117
-973,309
| -95% | -$27.7M |
|
|
IMGN
3465
CALL
DELISTED
Immunogen Inc
IMGN
| $1.89M | ﹤0.01% |
100,000
-544,500
| -84% | -$6.43M |
|
3466
CALL
Establishment Labs
ESTA
$2.11B
| $1.89M | ﹤0.01% |
27,500
-2,500
| -8% | -$173K |
|
3467
CALL
Cognizant
CTSH
$28.8B
| $1.89M | ﹤0.01% |
28,900
-162,300
| -85% | -$10.1M |
|
3468
Omeros
OMER
$1.35B
| $1.88M | ﹤0.01% |
345,864
+11,529
| +3% | +$67.3K |
|
|
PLL
3469
PUT
DELISTED
Piedmont Lithium
PLL
| $1.88M | ﹤0.01% |
+32,600
| New | +$1.87M |
|
3470
PUT
State Street
STT
$53.1B
| $1.88M | ﹤0.01% |
+25,700
| New | +$1.85M |
|
3471
KALA BIO
KALA
$13.3M
| $1.88M | ﹤0.01% |
2,577
-292
| -10% | -$227K |
|
3472
PUT
AGNC Investment
AGNC
$12.9B
| $1.88M | ﹤0.01% |
185,400
| – | – |
|
3473
AXT Inc
AXTI
$3.84B
| $1.88M | ﹤0.01% |
545,288
+519,349
| +2,002% | +$1.75M |
|
3474
CALL
Teradyne
TER
$55.5B
| $1.87M | ﹤0.01% |
16,800
-41,700
| -71% | -$4.18M |
|
|
SRDX
3475
PUT
DELISTED
Surmodics
SRDX
| $1.87M | ﹤0.01% |
+59,600
| New | +$1.36M |
|
Similar funds
Israel Englander's Q2 2023 Portfolio in Review
As of Q2 2023, Israel Englander held 7,181 positions worth $203B, up 16% from $174B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Israel Englander's Q2 2023 filing shows 870 new, 2,213 increased, 2,337 reduced and 1,192 closed positions. Its largest new stake was ResMed: 632,015 shares worth $138M. The largest sale was Tesla, an estimated $491M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 53% a quarter earlier, followed by Technology and Healthcare.
- Israel Englander's largest Q2 2023 buy was ResMed: 632,015 shares worth $138M.
- Israel Englander added most to iShares Core S&P 500 ETF in Q2 2023, an estimated $1.59B increase.
- Israel Englander's biggest Q2 2023 reduction was Tesla, cutting an estimated $491M.
- Israel Englander fully exited Shaw Communications Inc. in Q2 2023, selling an estimated $237M.
- Israel Englander's ten largest holdings make up 26% of its $203B portfolio in Q2 2023.
- Israel Englander opened 870 new positions and closed 1,192 in Q2 2023.
- Israel Englander's portfolio value rose 16% quarter-over-quarter to $203B.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.